Cargando…

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer

Mycobacteria Bovis osteomyelitis is a rare adverse effect after Bacillus Calmette-Guerin (BCG) intravesical therapy. A 62-year-old male presented with acute spinal cord compression three months after completing his second course of therapy for bladder cancer. The first course with intravesical BCG w...

Descripción completa

Detalles Bibliográficos
Autores principales: Seegobin, Karan, Maharaj, Satish, Baldeo, Cherisse, Isache, Carmen, Gharia, Bharatsinh, Zuberi, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635337/
https://www.ncbi.nlm.nih.gov/pubmed/29034173
http://dx.doi.org/10.1016/j.idcr.2017.09.008
_version_ 1783270266948812800
author Seegobin, Karan
Maharaj, Satish
Baldeo, Cherisse
Isache, Carmen
Gharia, Bharatsinh
Zuberi, Lara
author_facet Seegobin, Karan
Maharaj, Satish
Baldeo, Cherisse
Isache, Carmen
Gharia, Bharatsinh
Zuberi, Lara
author_sort Seegobin, Karan
collection PubMed
description Mycobacteria Bovis osteomyelitis is a rare adverse effect after Bacillus Calmette-Guerin (BCG) intravesical therapy. A 62-year-old male presented with acute spinal cord compression three months after completing his second course of therapy for bladder cancer. The first course with intravesical BCG was complicated with an episode of hematuria. He reported intermittent subjective fever for 3 weeks thereafter which resolved with Tylenol. Interferon-α2 B was added to the second cycle of intravesical BCG with the indication here being residual tumor, and was tolerated well. His complete blood count and liver function tests were unremarkable on admission. MRI showed features of osteomyelitis with cord compression at T4/T5. Biopsy of the affected bone showed caseating granuloma which was positive for acid fact bacilli, later confirmed to be Mycobacterium Bovis by PCR and pyrazinamide resistance. He was started on intravenous steroids and underwent spinal cord decompression. Rifampin, Isoniazid, and Ethambutol were then commenced. His weakness improved and after two months of therapy he was asymptomatic and back to his baseline function. Osteomyelitis is a rare but serious complication. Early diagnosis and treatment is important as the outcomes are good.
format Online
Article
Text
id pubmed-5635337
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56353372017-10-13 Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer Seegobin, Karan Maharaj, Satish Baldeo, Cherisse Isache, Carmen Gharia, Bharatsinh Zuberi, Lara IDCases Article Mycobacteria Bovis osteomyelitis is a rare adverse effect after Bacillus Calmette-Guerin (BCG) intravesical therapy. A 62-year-old male presented with acute spinal cord compression three months after completing his second course of therapy for bladder cancer. The first course with intravesical BCG was complicated with an episode of hematuria. He reported intermittent subjective fever for 3 weeks thereafter which resolved with Tylenol. Interferon-α2 B was added to the second cycle of intravesical BCG with the indication here being residual tumor, and was tolerated well. His complete blood count and liver function tests were unremarkable on admission. MRI showed features of osteomyelitis with cord compression at T4/T5. Biopsy of the affected bone showed caseating granuloma which was positive for acid fact bacilli, later confirmed to be Mycobacterium Bovis by PCR and pyrazinamide resistance. He was started on intravenous steroids and underwent spinal cord decompression. Rifampin, Isoniazid, and Ethambutol were then commenced. His weakness improved and after two months of therapy he was asymptomatic and back to his baseline function. Osteomyelitis is a rare but serious complication. Early diagnosis and treatment is important as the outcomes are good. Elsevier 2017-09-28 /pmc/articles/PMC5635337/ /pubmed/29034173 http://dx.doi.org/10.1016/j.idcr.2017.09.008 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Seegobin, Karan
Maharaj, Satish
Baldeo, Cherisse
Isache, Carmen
Gharia, Bharatsinh
Zuberi, Lara
Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title_full Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title_fullStr Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title_full_unstemmed Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title_short Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
title_sort mycobacteria bovis osteomyelitis following intravesical bcg for bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635337/
https://www.ncbi.nlm.nih.gov/pubmed/29034173
http://dx.doi.org/10.1016/j.idcr.2017.09.008
work_keys_str_mv AT seegobinkaran mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer
AT maharajsatish mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer
AT baldeocherisse mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer
AT isachecarmen mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer
AT ghariabharatsinh mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer
AT zuberilara mycobacteriabovisosteomyelitisfollowingintravesicalbcgforbladdercancer